Related Experiment Video
Updated: May 21, 2026
08:51
Cerebellar Regional Dissection for Molecular Analysis
Published on: December 5, 2020
Recent developments in Friedreich's ataxia: a state-of-the-art review
Laura R Chapman1,2, Heather Mortiboys1, Pamela J Shaw1,3
1Sheffield Institute for Translational Neuroscience, School of Medicine and Population Health, University of Sheffield, 385a Glossop Road, Sheffield, S10 2HQ, UK.
Brain Communications
|May 20, 2026
Summary
Friedreich's Ataxia (FRDA) is a rare, inherited neurological disorder. Recent research reviews cellular changes and trialed medications, highlighting knowledge gaps for developing new FRDA therapies.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Friedreich's Ataxia (FRDA) is a progressive, autosomal recessive inherited ataxia, common in specific global populations.
- It is a life-limiting condition with an average onset-to-death duration of 36 years.
- Historically, a lack of phenotypic certainty hindered licensed FRDA medication development.
Purpose of the Study:
- To critically review studies on FRDA from 1999 to December 2024.
- To identify common themes in cellular phenotypical changes and trialed medications for FRDA.
- To analyze discrepancies in research findings and discuss knowledge gaps impacting therapeutic development.
Main Methods:
- Conducted a critical literature review of 139 relevant studies.
- Utilized search terms including 'Friedreich's Ataxia', 'FRDA', 'inherited ataxias', 'recent developments', 'new treatments', and 'phenotype'.
- Analyzed common themes such as mitochondrial and iron dysregulation, and reviewed medication trial outcomes.
Main Results:
- Established links between frataxin deficiency, mitochondrial dysfunction, and iron dysregulation in FRDA.
- Identified common cellular phenotypical changes, both established and hypothesized.
- Reviewed various medications trialed for FRDA and their respective outcomes.
Conclusions:
- The review clarifies current knowledge on FRDA pathophysiology, particularly frataxin deficiency's role.
- It highlights significant gaps in understanding FRDA, impacting the development of effective therapeutic strategies.
- Future research directions are proposed to guide the development of novel FRDA therapies.
Related Concept Videos
01:18ATP Synthase: Structure
ATP synthase or ATPase is among the most conserved proteins found in bacteria, mammals, and plants. This enzyme can catalyze a forward reaction in response to the electrochemical gradient, producing ATP from ADP and inorganic phosphate. ATP synthase can also work in a reverse direction by hydrolyzing ATP and generating an electrochemical gradient. Different forms of ATP synthases have evolved special features to meet the specific demands of the cell. Based on their specific feature, ATP...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:48ATP Synthase: Mechanism
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased ATP...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...